scFv(CD20)-41BB-CD3zeta CAR-T Lentivirus

With the continuous innovation in cancer treatment, immune cell therapy (ICT) has become a highly sought-after treatment approach. It aims to fight cancer by activating or enhancing the patient''s own immune system. The core concept of this type of therapy is to harness the natural killer function of immune cells to enhance their ability to recognize and eliminate cancer cells. Immune cell therapies encompass various forms, including cytokine-induced killer (CIK) cell therapy, T cell therapy, chimeric antigen receptor T cell therapy (CAR-T cell therapy), and chimeric antigen receptor natural killer (CAR-NK) cell therapy. Lentivirus transfection technology plays a crucial role in immune cell therapy, particularly in the critical stages of gene editing and cell engineering.

Lentiviruses are a type of virus that can infect human and other mammalian cells. Derived from HIV-1, they have been safely modified to serve as ideal tools for researchers to deliver specific target genes. They belong to the retroviridae family. Retroviruses are characterized by carrying an RNA genome that is transcribed into DNA by a protein called reverse transcriptase, which is then integrated into the host cell genome by an enzyme called integrase. Because lentiviruses can integrate their sequences into the host genome, they enable long-term, stable gene expression and can infect both dividing and non-dividing cells.